170 related articles for article (PubMed ID: 12515619)
1. [Influence of thalidomide on interleukin-6 and its transmission in multiple myeloma patients].
Li J; Luo S; Hong W; Zhou Z; Zou W
Zhonghua Zhong Liu Za Zhi; 2002 May; 24(3):254-6. PubMed ID: 12515619
[TBL] [Abstract][Full Text] [Related]
2. [Influence of thalidomide on bone marrow microenvironment in refractory and relapsed multiple myeloma].
Li J; Luo SK; Hong WD; Zhou ZH; Zou WY
Ai Zheng; 2003 Apr; 22(4):346-9. PubMed ID: 12703985
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
4. Circulating IL-6-type cytokines and sIL-6R in patients with multiple myeloma.
Wierzbowska A; Urbańska-Ryś H; Robak T
Br J Haematol; 1999 May; 105(2):412-9. PubMed ID: 10233412
[TBL] [Abstract][Full Text] [Related]
5. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
6. Influence of thalidomide on Bcl2 expression and proangiogenic cytokine levels in short-term culture of peripheral blood and bone marrow mononuclear cells of multiple myeloma patients.
Dmoszyńska A; Roliński J; Bojarska-Junak A; Mańko J; Jawniak D; Walter-Croneck A; Soroka-Wojtaszko M; Hus M
Pol J Pharmacol; 2001; 53(6):709-13. PubMed ID: 11985351
[TBL] [Abstract][Full Text] [Related]
7. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
[TBL] [Abstract][Full Text] [Related]
8. [Soluble interleukin-6 receptors in the serum in multiple myeloma].
Scudla V; Kubalová D; Bacovský J; Lukes J; Vavrdová V
Cas Lek Cesk; 1996 Nov; 135(22):719-22. PubMed ID: 8998823
[TBL] [Abstract][Full Text] [Related]
9. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of soluble interleukin-6 receptor in patients with multiple myeloma.
Stasi R; Brunetti M; Parma A; Di Giulio C; Terzoli E; Pagano A
Cancer; 1998 May; 82(10):1860-6. PubMed ID: 9587117
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide treatment down-regulates SDF-1alpha and CXCR4 expression in multiple myeloma patients.
Oliveira AM; Maria DA; Metzger M; Linardi C; Giorgi RR; Moura F; Martinez GA; Bydlowski SP; Novak EM
Leuk Res; 2009 Jul; 33(7):970-3. PubMed ID: 18976811
[TBL] [Abstract][Full Text] [Related]
12. The influence of thalidomide therapy on cytokine secretion, immunophenotype, BCL-2 expression and microvessel density in patients with resistant or relapsed multiple myeloma.
Dmoszynska A; Podhorecka M; Manko J; Bojarska-Junak A; Rolinski J; Skomra D
Neoplasma; 2005; 52(2):175-81. PubMed ID: 15800717
[TBL] [Abstract][Full Text] [Related]
13. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma.
Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC
Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364
[TBL] [Abstract][Full Text] [Related]
14. Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy.
Gaillard JP; Bataille R; Brailly H; Zuber C; Yasukawa K; Attal M; Maruo N; Taga T; Kishimoto T; Klein B
Eur J Immunol; 1993 Apr; 23(4):820-4. PubMed ID: 8458373
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic effectiveness of thalidomide to multiple myeloma and its mechanism].
Wang M; Liu Y; Li Y; Wu H
Zhonghua Xue Ye Xue Za Zhi; 2002 Oct; 23(10):514-6. PubMed ID: 12482346
[TBL] [Abstract][Full Text] [Related]
16. Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Rosiñol L; Cibeira MT; Segarra M; Cid MC; Filella X; Aymerich M; Rozman M; Arenillas L; Esteve J; Bladé J; Montserrat E
Cytokine; 2004 May; 26(4):145-8. PubMed ID: 15149630
[TBL] [Abstract][Full Text] [Related]
17. Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells.
Keller ET; Ershler WB
J Immunol; 1995 Apr; 154(8):4091-8. PubMed ID: 7706747
[TBL] [Abstract][Full Text] [Related]
18. Involvement of hepcidin in the anemia of multiple myeloma.
Sharma S; Nemeth E; Chen YH; Goodnough J; Huston A; Roodman GD; Ganz T; Lichtenstein A
Clin Cancer Res; 2008 Jun; 14(11):3262-7. PubMed ID: 18519751
[TBL] [Abstract][Full Text] [Related]
19. [Expression and clinical significance of beta-catenin in multiple myeloma].
Li J; Zhang DB; Luo SK; Zhao Y; Huang BH; Gu JL
Ai Zheng; 2007 Sep; 26(9):1010-4. PubMed ID: 17927863
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma.
Vacca A; Scavelli C; Montefusco V; Di Pietro G; Neri A; Mattioli M; Bicciato S; Nico B; Ribatti D; Dammacco F; Corradini P
J Clin Oncol; 2005 Aug; 23(23):5334-46. PubMed ID: 15939924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]